{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:57:06Z","timestamp":1784883426103,"version":"3.55.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41575-026-01177-w","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:28:33Z","timestamp":1771500513000},"page":"370-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reply to \u2018The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view\u2019"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-9784","authenticated-orcid":false,"given":"Christophe","family":"Corpechot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Carlota","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Villamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Ytting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-5283","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-7799","authenticated-orcid":false,"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"1177_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41575-025-01135-y","volume":"22","author":"C Corpechot","year":"2025","unstructured":"Corpechot, C. et al. Bezafibrate for primary biliary cholangitis: time to act on the evidence. Nat. Rev. Gastroenterol. Hepatol. 22, 805\u2013807 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1177_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-026-01179-8","author":"DEJ Jones","year":"2026","unstructured":"Jones, D. E. J. et al. The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view. Nat. Rev. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1038\/s41575-026-01179-8 (2026).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1177_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","volume":"75","author":"A Tanaka","year":"2021","unstructured":"Tanaka, A. et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J. Hepatol. 75, 565\u2013571 (2021).","journal-title":"J. Hepatol."},{"key":"1177_CR4","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003879","author":"MC van Hooff","year":"2025","unstructured":"van Hooff, M. C. et al. Effectiveness and tolerability of bezafibrate in primary biliary cholangitis: a nationwide real-world study. Am. J. Gastroenterol. https:\/\/doi.org\/10.14309\/ajg.0000000000003879 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"1177_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince, M., Chetwynd, A., Newman, W., Metcalf, J. V. & James, O. F. W. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123, 1044\u20131051 (2002).","journal-title":"Gastroenterology"},{"key":"1177_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/hep.21871","volume":"46","author":"C Corpechot","year":"2007","unstructured":"Corpechot, C. & Poupon, R. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Hepatology 46, 963\u2013965 (2007).","journal-title":"Hepatology"},{"key":"1177_CR7","doi-asserted-by":"crossref","first-page":"487A","DOI":"10.1002\/hep.23607","volume":"52","author":"C Rigamonti","year":"2010","unstructured":"Rigamonti, C. et al. Primary biliary cirrhosis (PBC) with baseline normal bilirubin and albumin concentrations: treatment with ursodeoxycholic acid (UDCA) improves liver-related and non liverrelated survival. Hepatology 52, 487A (2010).","journal-title":"Hepatology"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01177-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:01:57Z","timestamp":1774915317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01177-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01177-w","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"19 February 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C. reports grants from Intercept Pharmaceuticals and Arrow G\u00e9n\u00e9riques, and consulting work for Cymabay, Gilead, Ipsen, Calliditas, GSK, Mirum, Advanz, Echosens and Intercept Pharmaceuticals. M.-C.L. reports grants from Gilead and Mirum, consulting work for Advanz, Mirum, Gilead, Ipsen, Falk and GSK, and lectures for Advanz, GSK, Gilead and Ipsen. H.Y. reports participation in advisory board for Ipsen and congress participation by invitation from Ipsen. A.V. reports speaker fees from Intercept. A.T. reports consultant work for GSK, Kowa, Kaken Pharmaceuticals, Ipsen, Mirum, Abbvie and Gilead. U.B. reports consulting and\/or lecture fees from Abacus, Amgen, Behring, GSK, Ipsen, Mirum, Ono.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}